- Home
- SRTS vs ENTX Comparison
SRTS vs ENTX Comparison
Compare SRTS & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | ENTX |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.3M | 74.7M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRTS | ENTX |
|---|---|---|
| Price | $5.07 | $1.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.00 | ★ $10.00 |
| AVG Volume (30 Days) | 122.2K | ★ 269.3K |
| Earning Date | 02-10-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,609,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $3.03 | $1.45 |
| 52 Week High | $9.08 | $3.22 |
Technical Indicators
Market Signals| Indicator | SRTS | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 36.56 |
| Support Level | $4.64 | $1.52 |
| Resistance Level | $5.36 | $1.64 |
| Average True Range (ATR) | 0.38 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 69.75 | 4.29 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.